Filing Analysis
Nu Skin Enterprises, Inc. announced that Justin Keisel, Executive Vice President and President of Global Sales, began a medical leave of absence effective August 17, 2026. Chayce Clark, the current COO and Chief Legal Officer, will oversee Keisel's organization during the leave.
🚩 Red Flags
- Sudden departure of a high-level executive (President of Global Sales) can create short-term leadership uncertainty.
📋 Key Facts
- Justin Keisel (EVP and President of Global Sales) began a medical leave of absence on August 17, 2026.
- Chayce Clark (EVP, COO, and Chief Legal Officer) will lead the Global Sales organization during the absence.
- The departure is due to medical reasons and is characterized as a leave of absence rather than a permanent resignation.
Nu Skin Enterprises, Inc. filed an 8-K to announce its financial results for the three- and six-month periods ended June 30, 2026. The filing serves as a formal announcement of quarterly earnings via a press release.
📋 Key Facts
- Report date: August 10, 2026
- Reporting period: Three- and six-month periods ended June 30, 2026
- The filing includes the announcement of financial results via Exhibit 99.1
- Signed by Chelsea K. Lantz, Chief Financial Officer
Nu Skin Enterprises, Inc. issued an 8-K to announce its financial results for the three- and nine-month periods ended September 30, 2025.
📋 Key Facts
- Report date: November 6, 2025
- Reporting period: Three- and nine-month periods ended September 30, 2025
- The filing includes a press release (Exhibit 99.1) regarding financial results.
- Information under Item 2.02 is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Nu Skin Enterprises, Inc. issued an 8-K to announce its financial results for the three- and six-month periods ended June 30, 2025.
📋 Key Facts
- Report date: August 7, 2025
- Reporting period covered: Three- and six-month periods ended June 30, 2025
- The filing includes a press release (Exhibit 99.1) regarding financial results.
- Information under Item 2.02 is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Nu Skin Enterprises, Inc. reported the results of its 2025 Annual Meeting of Stockholders held on May 29, 2025. The meeting resulted in the approval of several key items, including the election of nine directors and an amended omnibus incentive plan.
🚩 Red Flags
- The Amended and Restated Plan received a notable amount of 'Against' votes (1,899,631) compared to other proposals, though it still passed.
📋 Key Facts
- Stockholders approved the Amended and Restated 2024 Omnibus Incentive Plan, which increases share authorization by 790,000 shares.
- The Plan's termination date was extended to May 29, 2035.
- Nine directors were elected to serve until their successors are duly elected or until earlier death/resignation.
- Stockholders provided advisory approval of executive compensation (Say-on-Pay).
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for 2025.
Nu Skin Enterprises, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2025.
📋 Key Facts
- Report date: May 8, 2025
- Reporting period: Three-month period ended March 31, 2025
- The filing includes a press release (Exhibit 99.1) detailing financial results and other information.
- Signed by James D. Thomas, Chief Financial Officer.
Nu Skin Enterprises, Inc. announced that Zheqing (Simon) Shen will not stand for re-election to the Board of Directors at the upcoming 2025 Annual Meeting of Stockholders due to other professional commitments.
📋 Key Facts
- Zheqing (Simon) Shen decided not to stand for re-election to the Board of Directors.
- The decision is effective at the Company's 2025 Annual Meeting of Stockholders.
- Reason cited: other professional commitments.
Nu Skin Enterprises, Inc. issued an 8-K to announce its financial results for the three-month and annual periods ended December 31, 2024.
📋 Key Facts
- Report date: February 13, 2025
- Reporting period: Three-month and annual periods ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) detailing financial performance.
- Information under Item 2.02 is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Nu Skin Enterprises, Inc. issued a press release announcing preliminary financial results for the three-month period ended December 31, 2024.
📋 Key Facts
- Report date: January 13, 2025
- Period covered: Three-month period ended December 31, 2024
- Content: Preliminary information regarding financial results and other related data
- The information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 of the Exchange Act.
Nu Skin Enterprises, Inc. has completed the sale of its subsidiary, Mavely Seller LLC, to Clout.io Holdings, Inc. for a total consideration of $230 million in cash and $20 million in stock.
🚩 Red Flags
- The transaction involves significant cash outflow/reallocation, though it results in a net cash inflow for the parent company.
- Risks noted regarding the ability of Mavely to continue providing services as anticipated post-sale.
📋 Key Facts
- Transaction closed on January 2, 2025.
- Total purchase price: $230 million cash (subject to adjustments) plus $20 million in Purchaser's common stock.
- Nu Skin expects to retain approximately $207 million in cash and $10 million in Purchaser's common stock after paying other equity holders.
- Mavely will continue to provide technology and social commerce capabilities to support Nu Skin’s affiliate marketing business via a services arrangement.
Nu Skin Enterprises, Inc. issued an 8-K to announce its financial results for the three- and nine-month periods ended September 30, 2024.
📋 Key Facts
- Report date: November 7, 2024
- Reporting period: Three- and nine-month periods ended September 30, 2024
- The filing includes a press release (Exhibit 99.1) detailing financial results.
- Information furnished under Item 2.02 is not considered 'filed' for purposes of Section 18 of the Exchange Act.
Nu Skin Enterprises, Inc. has adopted its Sixth Amended and Restated Bylaws as of October 31, 2024. The amendments primarily focus on tightening procedural and disclosure requirements for stockholder nominations and proposals.
🚩 Red Flags
- Increased barriers to entry for shareholder activism/nominations (standard defensive measure).
📋 Key Facts
- Board approved and adopted the Sixth Amended and Restated Bylaws on October 31, 2024.
- Amendments include stricter disclosure requirements for stockholders intending to nominate director candidates or propose business.
- Nominees must now submit a D&O questionnaire and agreements regarding voting commitments and compensation.
- The Company may request additional information regarding the independence, background, and experience of stockholder nominees.
- Clarified procedures for nominations at special meetings of stockholders.
Nu Skin Enterprises, Inc. announced the appointment of Mark A. Zorko to its Board of Directors on September 10, 2024. His appointment increases the board size from eight to nine members and includes roles on the Audit and Nominating/Corporate Governance Committees.
📋 Key Facts
- Mark A. Zorko appointed as a director effective September 10, 2024.
- Board size increased from eight to nine members.
- Mr. Zorko will serve on the Audit Committee and the Nominating and Corporate Governance Committee.
- Compensation for Mr. Zorko will be pro-rated to 75% of standard amounts due to his mid-term appointment.
- The Company expects an indemnification agreement with Mr. Zorko substantially identical to existing agreements.
Nu Skin Enterprises, Inc. filed an 8-K to announce its financial results for the three and six-month periods ended June 30, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly/semi-annual financial results (Item 2.02).
- Reporting period covers the three- and six-month periods ended June 30, 2024.
- The press release containing the actual data is attached as Exhibit 99.1.
Nu Skin Enterprises, Inc. reported the results of its 2024 Annual Meeting of Stockholders held on June 5, 2024. The meeting included the election of eight directors and the approval of several key shareholder proposals, including a new omnibus incentive plan.
🚩 Red Flags
- Notable shareholder dissent regarding the 2024 Omnibus Incentive Plan (approx. 7% of voting shares cast against).
📋 Key Facts
- Stockholders approved the '2024 Omnibus Incentive Plan,' which supersedes the previous 2010 Plan.
- The 2024 Plan allows for various share-based awards (options, RSUs, etc.) and expires on June 5, 2034.
- Eight directors were elected to serve until their successors are duly elected or until death/resignation/removal.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for 2024.
- The 2024 Omnibus Incentive Plan received significant opposition, with 2,561,619 votes 'Against' compared to 35,854,226 'For'.
Nu Skin Enterprises, Inc. issued an 8-K to announce its financial results for the three-month period ended March 31, 2024.
📋 Key Facts
- Report date: May 8, 2024
- Reporting period: Three months ended March 31, 2024
- The filing includes a press release (Exhibit 99.1) regarding financial results and other information.
- Information under Item 2.02 is not considered 'filed' for purposes of Section 18 of the Exchange Act.
Nu Skin Enterprises, Inc. announced that Andrew Lipman will retire from the Board of Directors and will not seek re-election at the 2024 Annual Meeting of Stockholders.
📋 Key Facts
- Andrew Lipman informed the Company on March 15, 2024, of his decision to retire from the Board.
- Lipman will not stand for re-election at the upcoming 2024 Annual Meeting of Stockholders.
- The departure is framed as a retirement rather than an immediate resignation or removal.
Nu Skin Enterprises announced the departure of its Chief Scientific Officer from his executive role effective March 30, 2024. The individual will transition to leading the Company's Scientific Advisory Board rather than leaving the company entirely.
🚩 Red Flags
- Downgrading of a key scientific role from an executive officer position to a non-executive position.
📋 Key Facts
- Joseph Chang is stepping down as Chief Scientific Officer on March 30, 2024.
- The Board of Directors has reclassified the CSO role from an executive officer position to a non-executive position.
- Dr. Chang will transition to leading the Company's Scientific Advisory Board.
- The filing also includes the release of financial results for the three-month and annual periods ended December 31, 2023 (Item 2.02).
Nu Skin Enterprises, Inc. has adopted its Fifth Amended and Restated Bylaws to align with Delaware General Corporation Law and update procedural requirements for stockholder meetings and director nominations.
🚩 Red Flags
- Increased procedural hurdles for stockholder nominations and proposals.
- Stricter compliance requirements for proxy solicitation by stockholders.
📋 Key Facts
- Board of Directors approved the Fifth Amended and Restated Bylaws on February 5, 2024.
- Amendments include alignment with DGCL Section 219 (stockholder list availability) and Section 222 (meeting adjournment).
- New rules require stockholders soliciting proxies to use a non-white proxy card color.
- Updated advance notice procedures for stockholder nominations/proposals: deadline set between 90 and 120 days prior to the anniversary of the last annual meeting.
- Nominating stockholders must now provide written consent from nominees, including an agreement to submit an irrevocable resignation if elected (per majority voting bylaws).
- Clarified mandatory advancement of legal expenses for former directors and officers, subject to repayment if indemnification is ultimately denied.
Nu Skin Enterprises, Inc. issued a press release announcing preliminary financial results for the three-month period ended December 31, 2023.
📋 Key Facts
- The filing was made on January 8, 2024.
- Contains preliminary information regarding financial results for the quarter ending December 31, 2023.
- Information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 of the Exchange Act.